Brief: Viracta Therapeutics Announces The Initiation Of Naval-1, A Global Pivotal Trial For The Treatment Of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma
01/06/2021 13:58
June 1 (Reuters) - Viracta Therapeutics Inc VIRX.O :
* VIRACTA THERAPEUTICS ANNOUNCES THE INITIATION OF NAVAL-1,
A
GLOBAL PIVOTAL TRIAL FOR THE TREATMENT OF RELAPSED/REFRACTORY
EPSTEIN-BARR VIRUS-POSITIVE LYMPHOMA
Source text for Eikon: ID:nPn9RrywRa
Further company coverage: VIRX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Viracta Therapeutics
See all newsBrief: Viracta Therapeutics Announces Wind Down Of Operations
Brief: Viracta Therapeutics Announces Closure Of Naval-1 Clinical Trial And Exploration Of Strategic Alternatives
Brief: Viracta Therapeutics Receives Notice Of Non-Compliance From Nasdaq
Viracta Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Viracta Therapeutics Reports Q3 2024 Financial Results And Provides Business Update